




# PHARMACEUTICAL 2018

Kintara Therapeutics Inc.  
Rank 201 of 342





# PHARMACEUTICAL 2018

Kintara Therapeutics Inc.  
Rank 201 of 342

The relative strengths and weaknesses of Kintara Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kintara Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Kintara Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 14% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	7,871
Cost of Goods Sold	0
Intangible Assets	40
Liabilities, Current	1,304
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	28
Other Net Income	-239
Other Revenues	0
Property and Equipment	0
Research and Development	5,004
Selling, General and Administrative Expense	3,317

Output Variable	Value in 1000 USD
Assets	7,911
Liabilities	1,332
Expenses	8,321
Revenues	0
Stockholders Equity	6,579
Net Income	-8,560
Comprehensive Net Income	-8,560
Economic Capital Ratio	60%